Researchers is demonstrably improved this course of an novel therapy for ATTR-CM, leveraging Attruby. Preliminary patient results indicates significant outcomes for individuals affected from a debilitating disease. The focus highlights BridgeBio's dedication to addressing unmet healthcare demands